Lupin gets new Pharmaceutical Research Head

BSE: 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, November 13, 2007: In it's intent to continually attract the best talent globally, Lupin Ltd. announced today the appointment of Ninad Deshpanday as President – Pharmaceutical Research and Development.

Ninad joins Lupin from AAIPharma, USA and has worked in the past at companies like Synta, Cardinal Health, TheraTech and Procter & Gamble. He has returned to India after 23 years and brings with him experience on a wide range of dosage forms such as controlled release, transdermal and depot injections in addition to working with NCE projects as well.

Speaking on the appointment, Dr. Desh Bandhu Gupta, Chairman Lupin Ltd. said "We are very excited with Ninad's joining. He will be responsible for building the company's drug delivery pipeline and delivering on higher level of innovation for complex generic products globally. We believe that Novel Drug Delivery Systems is a huge space in the global pharmaceutical arena and is one that has been largely ignored by the Indian Pharmaceutical industry. With Ninad's expertise we look forward to taking our formulation research to higher levels, especially as far as drug delivery is concerned".

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the half year ended September 2007, Lupin's consolidated Revenues and Profit after Tax were Rs. 12669 million (US\$ 320 million) and Rs. 1314 million (US\$ 33 million) respectively.

For further information contact:

Raju Kane The Source

Tel. +91 22 24901327/28 Telefax: +91 22 24901325 Mobile: +91 98200 45656

E-mail: rajukane@sourcepr.com